These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 23253821)

  • 1. Metabolic risk factors in first-episode schizophrenia: baseline prevalence and course analysed from the European First-Episode Schizophrenia Trial.
    Fleischhacker WW; Siu CO; Bodén R; Pappadopulos E; Karayal ON; Kahn RS;
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):987-95. PubMed ID: 23253821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review.
    De Hert M; Schreurs V; Sweers K; Van Eyck D; Hanssens L; Sinko S; Wampers M; Scheen A; Peuskens J; van Winkel R
    Schizophr Res; 2008 Apr; 101(1-3):295-303. PubMed ID: 18299188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST.
    Rybakowski JK; Vansteelandt K; Remlinger-Molenda A; Fleischhacker WW; Kahn RS; Peuskens J;
    Eur Neuropsychopharmacol; 2014 Sep; 24(9):1500-5. PubMed ID: 25085534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiometabolic risk in first-episode schizophrenia (FES) patients with the earliest stages of both illness and antipsychotic treatment.
    Zhai D; Cui T; Xu Y; Feng Y; Wang X; Yang Y; Li S; Zhou D; Dong G; Zhao Y; Yang Y; Zhang R
    Schizophr Res; 2017 Jan; 179():41-49. PubMed ID: 27613506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effects of antipsychotic drugs on insight in first episode schizophrenia: Data from the European First-Episode Schizophrenia Trial (EUFEST).
    Pijnenborg GH; Timmerman ME; Derks EM; Fleischhacker WW; Kahn RS; Aleman A
    Eur Neuropsychopharmacol; 2015 Jun; 25(6):808-16. PubMed ID: 25907250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of depression in first episode of schizophrenia: results from EUFEST.
    Rybakowski JK; Vansteelandt K; Szafranski T; Thys E; Jarema M; Wolfgang Fleischhacker W; Kahn RS; Peuskens J;
    Eur Neuropsychopharmacol; 2012 Dec; 22(12):875-82. PubMed ID: 22627166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST).
    Boter H; Peuskens J; Libiger J; Fleischhacker WW; Davidson M; Galderisi S; Kahn RS;
    Schizophr Res; 2009 Dec; 115(2-3):97-103. PubMed ID: 19819114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial.
    Fleischhacker WW; Keet IP; Kahn RS;
    Schizophr Res; 2005 Oct; 78(2-3):147-56. PubMed ID: 16055308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications.
    Jerrell JM; McIntyre RS; Tripathi A
    Clin Schizophr Relat Psychoses; 2010 Oct; 4(3):161-8. PubMed ID: 20880826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.
    Falissard B; Mauri M; Shaw K; Wetterling T; Doble A; Giudicelli A; De Hert M
    Int Clin Psychopharmacol; 2011 Nov; 26(6):291-302. PubMed ID: 21876442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.
    Saddichha S; Manjunatha N; Ameen S; Akhtar S
    Schizophr Res; 2008 Apr; 101(1-3):266-72. PubMed ID: 18262771
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST).
    Davidson M; Galderisi S; Weiser M; Werbeloff N; Fleischhacker WW; Keefe RS; Boter H; Keet IP; Prelipceanu D; Rybakowski JK; Libiger J; Hummer M; Dollfus S; López-Ibor JJ; Hranov LG; Gaebel W; Peuskens J; Lindefors N; Riecher-Rössler A; Kahn RS
    Am J Psychiatry; 2009 Jun; 166(6):675-82. PubMed ID: 19369319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender differences in the treatment of first-episode schizophrenia: Results from the European First Episode Schizophrenia Trial.
    Ceskova E; Prikryl R; Libiger J; Svancara J; Jarkovsky J
    Schizophr Res; 2015 Dec; 169(1-3):303-307. PubMed ID: 26545298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
    Pérez-Iglesias R; Martínez-García O; Pardo-Garcia G; Amado JA; Garcia-Unzueta MT; Tabares-Seisdedos R; Crespo-Facorro B
    Int J Neuropsychopharmacol; 2014 Jan; 17(1):41-51. PubMed ID: 24103107
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
    Meyer JM; Davis VG; Goff DC; McEvoy JP; Nasrallah HA; Davis SM; Rosenheck RA; Daumit GL; Hsiao J; Swartz MS; Stroup TS; Lieberman JA
    Schizophr Res; 2008 Apr; 101(1-3):273-86. PubMed ID: 18258416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atypical antipsychotic drugs, schizophrenia, and metabolic syndrome in non-Euro-American societies.
    Bou Khalil R
    Clin Neuropharmacol; 2012; 35(3):141-7. PubMed ID: 22592510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of adiponectin and metabolic syndrome among patients taking atypical antipsychotics for schizophrenia: a cohort study.
    Bai YM; Chen TT; Yang WS; Chi YC; Lin CC; Liou YJ; Wang YC; Su TP; Chou P; Chen JY
    Schizophr Res; 2009 Jun; 111(1-3):1-8. PubMed ID: 19409756
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metabolic risk during antipsychotic treatment in patients with schizophrenia].
    Rzewuska M
    Psychiatr Pol; 2007; 41(4):457-72. PubMed ID: 18046977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physical health in schizophrenia: a challenge for antipsychotic therapy.
    Heald A
    Eur Psychiatry; 2010 Jun; 25 Suppl 2():S6-11. PubMed ID: 20620888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.